Literature DB >> 11042467

RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes.

A M Schmidt1, D M Stern.   

Abstract

Although the underlying causes of hyperglycemia are multiple, a common thread associated with high levels of blood sugar is the development of a range of vascular and inflammatory complications that might seriously limit the quality and duration of life in affected individuals. Despite multiple aggressive efforts to prevent complications, diabetes remains the leading disease consuming healthcare dollars in the USA. This review focuses on the role of advanced glycation endproducts (AGEs) and their interaction with their signal-transduction AGE receptor (RAGE), in vascular and inflammatory cell perturbation and the chronic activation that underlies diabetes. Our studies provide mechanistic insights into complications within the macrovasculature and those ensuing from an exaggerated host response to invading bacteria, and suggest that blockade of RAGE might provide a potent and safe strategy for the prevention of complications that typify long-term diabetes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11042467     DOI: 10.1016/s1043-2760(00)00311-8

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  42 in total

Review 1.  Inflammation in nonhealing diabetic wounds: the space-time continuum does matter.

Authors:  G F Pierce
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

2.  Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK).

Authors:  Ana M Cortizo; María G Lettieri; Daniel A Barrio; Natalia Mercer; Susana B Etcheverry; Antonio D McCarthy
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

3.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.

Authors:  Hideto Yonekura; Yasuhiko Yamamoto; Shigeru Sakurai; Ralica G Petrova; Md Joynal Abedin; Hui Li; Kiyoshi Yasui; Masayoshi Takeuchi; Zenji Makita; Shin Takasawa; Hiroshi Okamoto; Takuo Watanabe; Hiroshi Yamamoto
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

4.  Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway.

Authors:  Jin H Li; Wansheng Wang; Xiao R Huang; Matthew Oldfield; Ann M Schmidt; Mark E Cooper; Hui Y Lan
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

5.  Diabetes-related microvascular and macrovascular diseases in the physical therapy setting.

Authors:  W Todd Cade
Journal:  Phys Ther       Date:  2008-09-18

6.  Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36.

Authors:  Weifei Zhu; Wei Li; Roy L Silverstein
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

Review 7.  Pharmacological treatment of diabetic neuropathic pain.

Authors:  Howard S Smith; Charles E Argoff
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

Review 8.  RAGE: a novel target for drug intervention in diabetic vascular disease.

Authors:  Barry I Hudson; Ann Marie Schmidt
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

9.  Effects of glycation of the model food allergen ovalbumin on antigen uptake and presentation by human dendritic cells.

Authors:  Tamara Hilmenyuk; Iris Bellinghausen; Bärbel Heydenreich; Anne Ilchmann; Masako Toda; Stephan Grabbe; Joachim Saloga
Journal:  Immunology       Date:  2009-11-16       Impact factor: 7.397

10.  N(epsilon)-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status.

Authors:  Khaled A Ahmed; Sekaran Muniandy; Ikram S Ismail
Journal:  J Clin Biochem Nutr       Date:  2008-12-27       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.